us conference And call. XXXX first thank quarter our everyone, for afternoon, you for joining Good results
our employees of say as providers, I continue would community we healthcare of that of essential begin, all and our we to on partners, personnel, and stand in support our patients clinical ongoing to operation. a the minimizing we Before while behalf like of and implement with disruption the plan We research acted our Covid-XX safety through everyone work ensure to involved programs, to pandemic. business accordingly aTyr to
by abide on in business to the burden virus order our ease and our the healthcare continue directives role families the spread system. our to to their of our government employees operate minimizing and and in We remotely play
let's our corporate quarterly Now with started get and update. review
During first XXXX aTyr development quarter progressed major collaboration development including trial period, in program of our the for the clinical and subsequent and new Covid-XX announcing entering patients. expanded in for a of ATYRXXXX
and us of pipeline our further our milestones. and discovery potentially value enabling sheet advance balance advanced also towards programs We to strengthened creating important programs these
quarter with investigational an following highlights begin, summarize I'll key respiratory announced in XXXX new and of we application. drug the the severe We Covid-XX from the FDA acceptance As complications patients X first subsequent Phase period. trial of
a leading Cancer Mercurio, poster a upcoming be researcher as of the of School Arthur we'll We Massachusetts cancer American and at to of company Advisor the Association Kyorin at for development to million. entered with that and commercialization into diseases interstitial agreement in and XXXX We license collaboration turned abstracts Pharmaceutical would for the upcoming Medical Society Annual presenting American Scientific two We Conference. and the the International Care appointment Medicine Respiratory the at for Critical American lung up $XXX the in Journal announced published Thoracic ILD be Meeting. for of together presented Dr. University the or a Japan Research
offering role program. of approximately a of in that cell synthetase We tRNA states in to Kong second common ILDs. raised a and the build a published announced public including seveal for disease throughput a the award antibody And further Nature accomplished in Immunology journal continue far development great our in His- building gross a of platform million bi-specific of a quarter. of government Cellular We paper engagement significant out plays NRPX grant XXXX to finally, high the we've make the highlighting the We've in Hong and we deal modulation progress development stock. range antibodies the Molecular quite proceeds a of from immune thus broad $XX.X essential
and Today, to the I update of clinical will candidate pulmonary therapeutic Phase sarcoidosis our our time as well in both provide take trial with an XXXX Phase some our on our lead including program status Xb/Xa research as Covid-XX in will with biology. Jill ongoing our development also programs of preclinical patients. in will trial for financial our and review comment conclude on a NRPX X tRNA our efforts position. I synthetase
program begin XXXX. from our an Let's update with of
the further selectively explore and bind unique and diseases. of XXXX this continue in significant in XXXX the a Critical two Care to and of we to of The its the compelling of it publication the confirm make in NRPX While the to announced we Respiratory target. immune-mediated Medicine. just signaling abstracts elucidate advance serious We of findings American last pathway diseases. that and NRPX properties the and validate week on attributes action clinically, key of role XXXX ability and inflammatory Journal mechanism candidate
expressed of role inflammation this and findings detectable demonstrate granuloma that we research, to granulomas patients. NRPX of within expression NRPX sarcoidosis that formation. cells in are known the play and on these an be immune longing Through is summary, that In key can report readily important detected skin samples
the therapeutic and molecular demonstrates is diseases the a its published and characterize novel target NPRX on immune bind specifically immune-mediated the XXXX effect highlight could These be of that selectively pathway to indicate signaling exert on potential basis its surface. cells. NRPX findings immunomodulatory XXXX the for cell Additional and research properties various
XXXX. for our discuss let's Now program clinical
on will patients with pulmonary trial sarcoidosis. in We Xb/Xa update an with our XXXX begin Phase
serious in drug-related no adverse online minimum observed double-blind ascending which interim of of sarcoidosis drug, announced controlled had reminder, tolerated XX safe pulmonary December, a In XX blinded received and dose events. who placebo we multiple to randomized patients. dose be a study well a one data is was patients clinical safety from this As generally trial sarcoidosis with
cohort due in second us our to this on enrollment Xb/Xa pandemic data allowing patients enrolling conduct, the In the monitoring completed cohort dose that first and move addition, during top from our At its X final Covid-XX our our our clinical aforementioned announced of review, and group line test trial X, its results we from dose timing milligram per quarter, of would study. per patients be kilogram and study. of in completion were March in independent study the to phase board We milligram safety time, impact X of that delayed. kilogram in X and our safety
While had patients have has in Recruitment cohort X X rates missed some sites pause. for sites doses, cohort study which cases remained many to active, their have of and to some led some our investigational in have discontinuation. slowed
May including risks. currently June. potentially while with at more trial ensure overall of to our to site strategy in evaluating our working study, the procedures prepare their each to are and than valuable place reopening I'm sites of for to all sites restart the closely We study. number putting end full plans see understand patients to or happy completion of open provider an minimizing required safety in starting incorporate patient the the report with early as at strategy We're institutional plans of enrollment the so recruiting some to to that are meets XX we patients,
XXXX in with and for and strategy Kyorin ILDs license entering by As we Japan. development a to progress commercialization the agreement back announced XXXX into continue our company Pharmaceutical we January, collaboration global in for of development
on activities initial remain are development relevant and Japan the agency, and in underway dialog medical track. commencing The agency for much very the work including with clinical pharmaceuticals regulatory devices
to turn Phase let's of in our Now Covid-XX XXXX X patients. trial
to injury be trial XXXX for some have responses As Covid-XX similarities in to an shown light t-cell serious the down-regulate excessive complications signaling, has response need and Covid-XX interstitial disease. to cytokine remarkable in dampening the these the Many for the severe fatal may of our effective which pulmonary been related XXXX implicated to both determine disease to t-cells. primarily Covid-XX inflammatory respiratory We we to shared best driven how of caused contribute immediate our sometimes preclinically see for in of cases. pandemic, inflammatory lung look in with own we the we in that crisis observed action Koba in the thereby learned by this course science patients chemokine early experienced treatments been those Covid-XX. severe by inflammatory to able sarcoidosis, lung lung
double-blind has regarding has injury. that patients. had properties, to and substantial been pathology this March of subset the disease compelling that FDA approached had will Covid-XX. Covid-XX In in of include We responses, one of testing announced potentially XXXX to April, hospital. that mechanical treat believe lung presents in accepted XXXX XXXX function Patients the Patients with three in each. administered will of placebo-controlled receive Covid-XX three with for trial study of randomized dose not patients XXXX XX Covid-XX enrolled do trial assigned positive who or severe application a these mechanism in animal the this announced IND targeting be to to By we models kilogram one patients placebo will XX opportunity in also respiratory action per our lung FDA be we anti-inflammatory complications the with addition of overlap hospitalized shown immune acute In require improve in immune of Phase mediated cohorts ventilation. we average of to either a The single XXXX milligrams respiratory severe X complication. patients or
treatment and centers to be we will XX for to the Patients post enroll plan in XX days up US. followed at
on outcome endpoint safety to While also setting, tolerability focus including in clinical dose and this biomarkers. of measures, a and we assess but the inflammatory single the study to of not hypoxia number key acute limited primary XXXX fever, of is will of
are with same pulmonary the engaged part our identified have of in are sites that throughout and trial. activities US sites including some target of sarcoidosis start-up the We
site first of aTyr the trial our initiation with is expect ready for The to an progresses. the first address provide XXXX further health program. fundamentally novel public crisis to important to this clinical dose in lung. to trial potentially therapy plan the enroll updates coming and inflammation We address and patient specifically aberrant We milestone as opportunity has our to weeks. a an be response designed immune this the within
Now program of as continue areas in to ILDs. we turn our including let's diseases our outside to NRPX research in pipeline opportunities, invest
antibodies settings and for continue NRPX the Our disorders. publish collaborations application validating inflammatory academic and of therapeutic Discovery and Program of yield and biology NRPX including a in-house and disease data cancer variety potential to Research
Mercurio is our body and evidence pleased cell then of in key cancer NRPX enriched of School. function cancer NRPX a collaboration is lab development. breast Medical his are breast critical signaling indicating with of be to There of the Massachusetts University growing stem the for one and expression stem working resistance that cells at advisors Dr. in We Arthur scientific , is and
collaboration the our NRPX Through This Dr. explore triple was strong target. one models. with provides in for a targeting negative of NRPX as a abstract of antibodies are American poster our that included this accepted use upcoming Mercurio, by Results in rationale from for and meeting an Research Association Cancer for its annual cancer we therapeutic the June. collaboration at breast
to through of our to external leverage collaboration. our new our company, of four broad IP. programs discovery Behring, look continue leading up candidates portfolio synthetase IND we collaboration we portfolio identify tRNA and CSL intellectual internal from synthetase with Biotherapeutics Finally, seek research to to property tRNA a global Through
of the the of primarily disruption to account have delay research program, for We in plans completing the Covid-XX extended the slight from pandemic. a to some due stage first our
committed collaboration this plan to year. have later program. parties for an Both this funding will achieving update collaboration are on the providing the continue. We milestones the in that on And of agreed
will see Overall, restarting X that enrollments shortly. We XXXX. date we be the have pulmonary are to cohort we trial pleased signs sarcoidosis our progress made in with
this two With data expect announcement trial we the from patients, XXXX are we year. And in investigating to trial Covid-XX later Covid-XX clinical in setting. the of now report
initiating clinical work programs published our established Kyorin partnerships. our in work through Our Japan data through internally research that We XXXX to to partnership our and science both continue discovery from also external for and look generate forward current validate
to Broadfoot to our over review that to like our Officer, With I'd financial Financial turn Chief Jill results. it
